• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

氟轻松醋酸酯眼内植入剂治疗非感染性葡萄膜炎患者的眼内压结果。

Intraocular pressure outcome of patients with fluocinolone acetonide intravitreal implant for noninfectious uveitis.

机构信息

Department of Ophthalmology, Medical College of Georgia, Augusta, Georgia, USA.

出版信息

Ophthalmology. 2011 Oct;118(10):1927-31. doi: 10.1016/j.ophtha.2011.02.042. Epub 2011 Jun 8.

DOI:10.1016/j.ophtha.2011.02.042
PMID:21652079
Abstract

PURPOSE

To evaluate the intraocular pressure (IOP) outcomes of patients with noninfectious posterior uveitis treated with a fluocinolone acetonide (FA) intravitreal implant over an 8-year period.

DESIGN

Retrospective clinical case series.

PARTICIPANTS

Forty-seven eyes of 35 patients.

METHODS

Retrospective review of medical records of all patients receiving FA implants between June 2001 and March 2009 was performed. Data were pooled to record visual acuity (VA) and to characterize the incidence and outcome of glaucoma surgical intervention.

MAIN OUTCOME MEASURES

Incidence of glaucoma surgery and IOP before and after glaucoma surgical intervention. Visual acuity before and after FA implant placement.

RESULTS

Nineteen of 42 eyes (45%) receiving FA implants over the course of the study period required glaucoma surgical intervention. Success of IOP-lowering surgery was achieved in 94%, 94%, and 92% of eyes at 6, 12, and 24 months postoperatively. No patient lost more than 1 line of VA. There was an average 2-line gain of acuity at 3 years after FA implant placement for those patients who underwent IOP-lowering surgery.

CONCLUSIONS

Patients receiving FA implants have a significant risk of increased IOP that frequently necessitates glaucoma surgery. Glaucoma surgery, when necessary, offers an effective method to decrease IOP.

FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

摘要

目的

评估氟轻松醋酸酯(FA)眼内植入物治疗非感染性后葡萄膜炎患者 8 年期间的眼压(IOP)结果。

设计

回顾性临床病例系列。

参与者

35 名患者的 47 只眼。

方法

对 2001 年 6 月至 2009 年 3 月期间接受 FA 植入物的所有患者的病历进行回顾性审查。汇总数据记录视力(VA)并描述青光眼手术干预的发生率和结果。

主要观察指标

青光眼手术的发生率和青光眼手术前后的 IOP。FA 植入前后的视力。

结果

在研究期间,42 只眼中有 19 只(45%)接受 FA 植入物,需要进行青光眼手术干预。术后 6、12 和 24 个月,降压手术成功率分别为 94%、94%和 92%。没有患者视力损失超过 1 行。在接受 IOP 降低手术的患者中,FA 植入后 3 年平均视力提高了 2 行。

结论

接受 FA 植入物的患者有明显的眼压升高风险,这常常需要进行青光眼手术。当需要时,青光眼手术是降低眼压的有效方法。

金融披露

参考文献后可能会有专有或商业披露。

相似文献

1
Intraocular pressure outcome of patients with fluocinolone acetonide intravitreal implant for noninfectious uveitis.氟轻松醋酸酯眼内植入剂治疗非感染性葡萄膜炎患者的眼内压结果。
Ophthalmology. 2011 Oct;118(10):1927-31. doi: 10.1016/j.ophtha.2011.02.042. Epub 2011 Jun 8.
2
Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma.联合氟轻松醋酸酯玻璃体腔内植入和青光眼引流装置植入治疗慢性葡萄膜炎和青光眼。
Am J Ophthalmol. 2010 May;149(5):800-6.e1. doi: 10.1016/j.ajo.2009.12.009. Epub 2010 Feb 26.
3
Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.用于非感染性后葡萄膜炎的醋酸氟轻松植入剂(Retisert):一项多中心随机临床研究的34周结果
Ophthalmology. 2006 Jun;113(6):1020-7. doi: 10.1016/j.ophtha.2006.02.021. Epub 2006 May 9.
4
Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.醋酸氟轻松植入剂治疗后葡萄膜炎的一项试点试验的长期随访结果
Ophthalmology. 2005 Jul;112(7):1192-8. doi: 10.1016/j.ophtha.2005.03.013.
5
Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis.评价玻璃体内注射氟轻松醋酸酯植入剂与标准全身治疗在非感染性后部葡萄膜炎中的效果。
Ophthalmology. 2010 Mar;117(3):567-75, 575.e1. doi: 10.1016/j.ophtha.2009.11.027. Epub 2010 Jan 15.
6
Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis.联合氟轻松丙酮奈德眼内给药系统植入、超声乳化术及人工晶状体植入治疗严重葡萄膜炎。
Am J Ophthalmol. 2008 Oct;146(4):589-594. doi: 10.1016/j.ajo.2008.05.035. Epub 2008 Jul 17.
7
Risk factors associated with intraocular pressure increase in patients with uveitis treated with the fluocinolone acetonide implant.与应用氟轻松水合物植入剂治疗的葡萄膜炎患者眼压升高相关的风险因素。
JAMA Ophthalmol. 2015 May;133(5):568-73. doi: 10.1001/jamaophthalmol.2015.51.
8
Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial.葡萄膜炎患者眼压升高和青光眼的风险:多中心葡萄膜炎皮质类固醇治疗试验的结果。
Ophthalmology. 2013 Aug;120(8):1571-9. doi: 10.1016/j.ophtha.2013.01.025. Epub 2013 Apr 16.
9
Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results.前瞻性研究氟轻松醋酸酯植入物治疗视网膜中央静脉阻塞所致慢性黄斑水肿:36 个月结果。
Ophthalmology. 2012 Jan;119(1):132-7. doi: 10.1016/j.ophtha.2011.06.019. Epub 2011 Sep 14.
10
Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.接受醋酸氟轻松植入物治疗的葡萄膜炎患者的眼压
Arch Ophthalmol. 2007 Nov;125(11):1478-85. doi: 10.1001/archopht.125.11.ecs70063. Epub 2007 Oct 8.

引用本文的文献

1
Mouse Model of Glucocorticoid-Induced Glaucoma.糖皮质激素诱导性青光眼的小鼠模型。
Methods Mol Biol. 2025;2858:131-141. doi: 10.1007/978-1-0716-4140-8_12.
2
Intravitreal steroid implants in the management of noninfectious intermediate and posterior uveitis.玻璃体内注射类固醇植入物在非感染性中间葡萄膜炎和后葡萄膜炎治疗中的应用
Indian J Ophthalmol. 2025 Jan 1;73(Suppl 1):S37-S46. doi: 10.4103/IJO.IJO_712_24. Epub 2024 Sep 19.
3
Role of Glucocorticoids and Glucocorticoid Receptors in Glaucoma Pathogenesis.糖皮质激素及其受体在青光眼发病机制中的作用。
Cells. 2023 Oct 14;12(20):2452. doi: 10.3390/cells12202452.
4
Corticosteroid implants for chronic non-infectious uveitis.皮质类固醇植入物治疗慢性非感染性葡萄膜炎。
Cochrane Database Syst Rev. 2023 Aug 29;8(8):CD010469. doi: 10.1002/14651858.CD010469.pub4.
5
Corticosteroid implants for chronic non-infectious uveitis.皮质类固醇植入物治疗慢性非感染性葡萄膜炎。
Cochrane Database Syst Rev. 2023 Jan 16;1(1):CD010469. doi: 10.1002/14651858.CD010469.pub3.
6
Long-term efficacy of dexamethasone intravitreal implant in the treatment of Vogt-Koyanagi-Harada disease relapsing posterior uveitis.地塞米松玻璃体内植入剂治疗 Vogt-小柳原田病复发后葡萄膜炎的长期疗效。
Indian J Ophthalmol. 2022 Jul;70(7):2465-2470. doi: 10.4103/ijo.IJO_260_22.
7
Intravitreal therapeutic agents in noninfectious uveitic macular edema.玻璃体内治疗药物治疗非感染性葡萄膜炎相关黄斑水肿。
Indian J Ophthalmol. 2018 Aug;66(8):1060-1073. doi: 10.4103/ijo.IJO_35_18.
8
Systemic lupus erythematosus and ocular involvement: an overview.系统性红斑狼疮与眼部受累:概述。
Clin Exp Med. 2018 May;18(2):135-149. doi: 10.1007/s10238-017-0479-9. Epub 2017 Dec 14.
9
Severe Corticosteroid-Induced Ocular Hypertension Requiring Bilateral Trabeculectomies in a Patient with Takayasu's Arteritis.一位患有高安动脉炎的患者出现严重皮质类固醇诱导的高眼压,需要双侧小梁切除术。
Case Rep Ophthalmol Med. 2016;2016:5253029. doi: 10.1155/2016/5253029. Epub 2016 Nov 10.
10
Management of noninfectious posterior uveitis with intravitreal drug therapy.玻璃体内药物治疗非感染性后葡萄膜炎的管理
Clin Ophthalmol. 2016 Oct 13;10:1983-2020. doi: 10.2147/OPTH.S89341. eCollection 2016.